# Caribou Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/caribou-biosciences

- Industry: Biotechnology
- Headquarters: Berkeley, US
- Website: www.cariboubio.com
- Total disclosed funding: $138M
- Latest round: Series C (Mar 2, 2021)
- Investors on record: 24

## About

Based in California, US, Caribou Biosciences Inc. was founded in 2011 by co-founders James Berger, Jennifer A. Doudna, Martin Jinek, and Rachel E. Haurwitz. The company is a clinical-stage CRISPR genome editing biotechnology company that creates a clinical-stage therapeutic and a pipeline of pre-clinical allogeneic CAR-T and CAR-NK cell therapies that are potentially transformative for patients. The company's investors include LifeSci Venture Partners, Farallon Capital Management, PFM Health Sciences, Ridgeback Capital and Avego Bioscience Capital. In 2014, Caribou Biosciences invested in Intellia Therapeutics. As of March 2021, the company has raised a total funding of USD 141 million and raised a Series C funding of USD 115 million. In July 2021, the company became a public company and got listed under the ticker symbol CRBU. As of July 2021, the company has 66 employees.

Caribou Biosciences provides two fundamental components of CRISPR systems: the nuclease protein(s) that cut DNA and the RNA molecule(s) that direct the nuclease to create a site-specific, double-stranded break, resulting in editing at the targeted genomic location. Caribou Biosciences created chRDNAs, also known as Chardonnays, which are RNA-DNA hybrid guides that direct more accurate genome editing than other RNA guides.

As of December 2020, the company has generated an annual revenue of USD 12,361.

The company plans to develop its proprietary, next-generation CRISPR technology platform and to advance its pipeline of wholly-owned allogeneic immune cell therapies for cancers.

## Funding rounds

- Series C, Mar 2, 2021, $115M — Invus [DUP], Tekla Capital Management, Adage Capital Management, Maverick Capital, The Leukemia & Lymphoma Society, AbbVie Ventures, Farallon Capital Management, Monashee Investment Management, Point72 Asset Management, Janus Henderson Investors, LifeSci Partners, Ridgeback Asset Management, Aliment Capital, Avidity Partners, Avego Bioscience Capital, Heritage Medical Systems, PFM Health Sciences
- Series B, May 12, 2016, $14M — F-Prime Capital, Pontifax Venture Capital, Mission Bay Capital, Maverick Capital, Anterra Capital, Genoa Ventures, Heritage Group, Novartis
- Series A, Mar 24, 2015, $8.6M — F-Prime Capital, Mission Bay Capital, Genoa Ventures, Novartis

## Investors

- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A, Series B
- Mission Bay Capital (https://capitalatlas.ai/funds/mission-bay-capital) — Series A, Series B
- Genoa Ventures (https://capitalatlas.ai/funds/genoa-ventures) — Series A, Series B
- Novartis — Series A, Series B
- Pontifax Venture Capital (https://capitalatlas.ai/funds/pontifax-venture-capital) — Series B
- Maverick Capital (https://capitalatlas.ai/funds/maverick-capital) — Series B, Series C
- Anterra Capital (https://capitalatlas.ai/funds/anterra-capital) — Series B
- Heritage Group — Series B
- Invus [DUP] — Series C
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series C
- Adage Capital Management — Series C
- The Leukemia & Lymphoma Society — Series C
- AbbVie Ventures (https://capitalatlas.ai/funds/abbvie-ventures) — Series C
- Farallon Capital Management (https://capitalatlas.ai/funds/farallon-capital-management) — Series C
- Monashee Investment Management — Series C
- Point72 Asset Management — Series C
- Janus Henderson Investors — Series C
- LifeSci Partners (https://capitalatlas.ai/funds/lifesci-partners) — Series C
- Ridgeback Asset Management — Series C
- Aliment Capital (https://capitalatlas.ai/funds/aliment-capital) — Series C
- Avidity Partners — Series C
- Avego Bioscience Capital — Series C
- Heritage Medical Systems — Series C
- PFM Health Sciences (https://capitalatlas.ai/funds/pfm-health-sciences) — Series C